ONO-7847 Phase 3 Study, A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of ONO-7847 for the Prevention of Cancer Chemotherapy-Induced Nausea and Vomiting in Patients with Malignant Tumor.

Trial Profile

ONO-7847 Phase 3 Study, A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of ONO-7847 for the Prevention of Cancer Chemotherapy-Induced Nausea and Vomiting in Patients with Malignant Tumor.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Fosaprepitant (Primary) ; Dexamethasone; Granisetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 11 Dec 2012 New trial record
    • 31 Oct 2012 Results published in the Annals of Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top